84 related articles for article (PubMed ID: 26784939)
1. No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans.
Long B; Su YQ; Xia Y; Zou YY; Tang B; Chen ZJ; Lin Y
Int J Clin Pharmacol Ther; 2016 Mar; 54(3):157-62. PubMed ID: 26784939
[TBL] [Abstract][Full Text] [Related]
2. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
3. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
[TBL] [Abstract][Full Text] [Related]
4. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol.
Siegmund W; Ludwig K; Giessmann T; Dazert P; Schroeder E; Sperker B; Warzok R; Kroemer HK; Cascorbi I
Clin Pharmacol Ther; 2002 Nov; 72(5):572-83. PubMed ID: 12426521
[TBL] [Abstract][Full Text] [Related]
5. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
[TBL] [Abstract][Full Text] [Related]
6. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
8. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
9. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
10. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
[TBL] [Abstract][Full Text] [Related]
11. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
12. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
Zeng Y; He FY; He YJ; Dai LL; Fan L; Zhou HH
Xenobiotica; 2009 Nov; 39(11):844-9. PubMed ID: 19845435
[TBL] [Abstract][Full Text] [Related]
13. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.
Siegmund W; Ludwig K; Engel G; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Weitschies W
J Pharm Sci; 2003 Mar; 92(3):604-10. PubMed ID: 12587122
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
[TBL] [Abstract][Full Text] [Related]
15. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers.
Fan L; Mao XQ; Tao GY; Wang G; Jiang F; Chen Y; Li Q; Zhang W; Lei HP; Hu DL; Huang YF; Wang D; Zhou HH
Xenobiotica; 2009 Mar; 39(3):249-54. PubMed ID: 19280523
[TBL] [Abstract][Full Text] [Related]
16. Effect of genistein on the activities of cytochrome P450 3A and P-glycoprotein in Chinese healthy participants.
Xiao CQ; Chen R; Lin J; Wang G; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2012 Feb; 42(2):173-8. PubMed ID: 21943317
[TBL] [Abstract][Full Text] [Related]
17. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
[TBL] [Abstract][Full Text] [Related]
18. MDR1 genotype do not influence the absorption of a single oral dose of 100 mg talinolol in healthy Chinese males.
Zhang WX; Chen GL; Zhang W; Tan ZR; Liu J; Zhou G; Hu DL; Zhou HH
Clin Chim Acta; 2005 Sep; 359(1-2):46-52. PubMed ID: 16170863
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
20. Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition.
Siegmund W; Altmannsberger S; Paneitz A; Hecker U; Zschiesche M; Franke G; Meng W; Warzok R; Schroeder E; Sperker B; Terhaag B; Cascorbi I; Kroemer HK
Clin Pharmacol Ther; 2002 Sep; 72(3):256-64. PubMed ID: 12235446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
